Gregory J. Tsongalis, Richard W. Cartun, Andrew Ricci Jr.
Gene Amplification as Means for Determining Therapeutic Strategies in Human Cancers
Pharmacogenomic analysis aspires to identify individuals
with specific genetic characteristics in order to
predict a positive response or reduce a negative response
to a therapeutic modality. While the search
continues for the many single nucleotide polymorphisms
which will be used in such genetic analyses,
other genetic alterations in specific cell types have
proven useful in determining the potential for response
to therapy. One such genetic alteration is amplification
of entire gene sequences which results in
overexpression of a gene product or protein. Amplification
of the HER2 (neu, erbB-2) oncogene is found in
up to 35% of human breast cancers and is associated
with a poor prognosis. In addition, this genetic alteration
may predict response to various therapeutic
modalities. Assays are available to detect the HER2
protein receptor or copies of the HER2 gene sequence
to determine eligibility for Herceptin treatment or adriamycin
treatment in node positive patients, respectively.
This model represents a somatic event used in
the functional determination of a therapeutic strategy.
Clinical Chemical Laboratory Medicine, Walter de Gruyter
Print ISSN: 1434-6621
Volume: 38, 09/2000
Pages: 837 - 839
Show full article (external site)
Show all available items of this journal